Conference Coverage (AACR)

T-Cell Response Stimulated from Dinitophenyl-Modified Autologous Melanoma Cells

Published in Vaccine Weekly, May 27th, 1996

Treatment with a dinitrophenol (DNP)-modified autologous melanoma vaccine demonstrated a T-cell response to DNP peptides in a human system.

T. Sato et al. designed a study to investigate peptide fractions eluted from a DNP-melanoma vaccine which stimulated specific T lymphocytes and presented the results at the 87th Annual Meeting of the American Association for Cancer Research, held April 20-24, 1996, in Washington, DC.

"Immunization with DNP-modified autologous melanoma cells induces T lymphocytes that recognize an MHC-associated DNP-modified peptide," stated Sato et al. "This is the first such demonstration in a human system."

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1996-05-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry